

REMARKS

Claims 61-77 and 83-87 are currently pending in this application, and Claim 49 is withdrawn. In the Office Action mailed April 4, 2006, Claims 61-77 and 83-87 are rejected under 35 U.S.C. §112(1) for failing to comply with the written description requirement. In the Office Action dated November 2, 2005 at page 3, the Examiner admitted that the “written description in this case has only set forth a method of activating NK cells using either a HSP protein of SEQ ID NO: 1, a C-terminal fragment comprising amino acids 384-641 of SEQ ID NO: 1” The claims have been amended to specify the use of these two polypeptides and the 70% homology limitation has been deleted. Accordingly, Applicants respectfully submit that the written description rejection is moot.

The Applicants believe that the amendments set forth above traverse the Examiner's rejections and, therefore, request that all grounds for rejection be withdrawn for the reasons set above. Should the Examiner believe that a telephone interview would aid in the prosecution of this application, the Applicants encourage the Examiner to call the undersigned collect at 608-218-6900.

Dated: November 16, 2007

/John Mitchell Jones/
John Mitchell Jones
Registration No. 44,174

CASIMIR JONES S.C.
440 Science Dr. Ste. 203
Madison WI 53711
608.218.6900